U

UroGen Pharma Ltd
D

URGN

10.100
USD
-0.60
(-5.61%)
مغلق
حجم التداول
7,130
الربح لكل سهم
-4
العائد الربحي
-
P/E
-3
حجم السوق
426,214,081
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    AGIO
    1.430
    (4.23%)
    35.210 USD
    C
    CRSP
    -2.620
    (-5.19%)
    47.840 USD
    E
    EXAS
    -0.270
    (-0.55%)
    49.250 USD
    F
    FGEN
    -0.09040
    (-11.70%)
    0.68200 USD
    I
    INCY
    0.790
    (1.11%)
    72.150 USD
    N
    NVCR
    0.420
    (1.94%)
    22.090 USD
    T
    TNDM
    -1.110
    (-3.45%)
    31.020 USD
    VRTX
    VRTX
    4.10
    (0.85%)
    484.53 USD
    المزيد
الأخبار
المقالات

العنوان: UroGen Pharma Ltd

القطاع: Healthcare
الصناعة: Biotechnology
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.